Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Cardiovasc Drugs ; 23(4): 393-406, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37188993

ABSTRACT

Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration (FDA) approved to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in adults. IPE is an esterified version of eicosapentaenoic acid (EPA) and acts as a prodrug in the body to exert its effects. IPE affects the body primarily through triglyceride (TG) reduction and was initially indicated for hypertriglyceridemia in addition to statin therapy or for patients with statin intolerances. Various studies have investigated this agent, and multiple subanalyses have been conducted since the FDA approval. These subanalyses have assessed factors such as sex, statin therapy, high-sensitivity C-reactive protein levels (hs-CRP), and various inflammatory biomarkers in groups of patients taking IPE. This article aims to provide a critical review of the clinical data available regarding cardiovascular benefits of IPE in patients with ASCVD and its value as a treatment option for patients with elevated TG levels.


Subject(s)
Atherosclerosis , Cardiovascular Diseases , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypertriglyceridemia , Humans , Eicosapentaenoic Acid/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/drug therapy , Risk Factors , Hypertriglyceridemia/drug therapy , Atherosclerosis/drug therapy , Atherosclerosis/prevention & control , Heart Disease Risk Factors , Triglycerides
SELECTION OF CITATIONS
SEARCH DETAIL
...